Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished date: 9 October 2019
High-intensity focused ultrasound for glaucoma (IPG661)Product type:GuidanceProgramme:Interventional procedures guidancePublished date: 25 September 2019
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 31 July 2019
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (part review of TA301) [ID1421]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 20 November 2019
Lifitegrast for treating dry eye disease [ID1229]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC
Brolucizumab for treating wet age-related macular degeneration [ID1254]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Abicipar pegol for treating wet age-related macular degeneration ID1533Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC
Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC
Repetitive short pulse transscleral cyclophotocoagulation for glaucomaStatus:In developmentProgramme:Interventional procedures guidanceExpected publication date: TBC